View in EDS

Risk of synchronous and second primary malignancies in transplant-ineligible patients with multiple myeloma treated with lenalidomide.

Saved in:
Bibliographic Details
Title: Risk of synchronous and second primary malignancies in transplant-ineligible patients with multiple myeloma treated with lenalidomide.
Authors: Systchenko T; Poitou-Charentes General Cancer Registry, Université de Poitiers, Poitiers, France.; INSERM Clinical Investigation Center 1402, University Hospital Center of Poitiers, Poitiers, France.; Hematology Department, University Hospital Center of Poitiers, Poitiers, France., Nsiala L; Poitou-Charentes General Cancer Registry, Université de Poitiers, Poitiers, France.; INSERM Clinical Investigation Center 1402, University Hospital Center of Poitiers, Poitiers, France.; Hematology Department, University Hospital Center of Poitiers, Poitiers, France., Bobin A; INSERM Clinical Investigation Center 1402, University Hospital Center of Poitiers, Poitiers, France.; Hematology Department, University Hospital Center of Poitiers, Poitiers, France., Gardeney H; INSERM Clinical Investigation Center 1402, University Hospital Center of Poitiers, Poitiers, France.; Hematology Department, University Hospital Center of Poitiers, Poitiers, France., Motard C; Hematology Department, Hospital Center of Niort, Niort, France., Olivier G; Hematology Department, Hospital Center of Niort, Niort, France., Borde F; Oncology Department, Hospital Center of Saintes, Saintes, France., Corby A; Hematology Department, Hospital Center of La Rochelle, La Rochelle, France., Roul C; Hematology Department, Hospital Center of La Rochelle, La Rochelle, France., Fleck E; Hematology Department, Hospital Center of La Rochelle, La Rochelle, France., Denis G; Internal Medicine Department, Hospital Center of Rochefort, Rochefort, France., Dieval C; Internal Medicine Department, Hospital Center of Rochefort, Rochefort, France., Mottaz P; Internal Medicine Department, Hospital Center of Royan, Royan, France., Boscagli A; Internal Medicine Department, Hospital Center of Royan, Royan, France., Defossez G; Poitou-Charentes General Cancer Registry, Université de Poitiers, Poitiers, France.; INSERM Clinical Investigation Center 1402, University Hospital Center of Poitiers, Poitiers, France., Leleu X; INSERM Clinical Investigation Center 1402, University Hospital Center of Poitiers, Poitiers, France.; Hematology Department, University Hospital Center of Poitiers, Poitiers, France.
Source: Blood advances [Blood Adv] 2025 Dec 09; Vol. 9 (23), pp. 6001-6008.
Publication Type: Journal Article
Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40864187
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Risk of synchronous and second primary malignancies in transplant-ineligible patients with multiple myeloma treated with lenalidomide.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Systchenko+T%22">Systchenko T</searchLink>; Poitou-Charentes General Cancer Registry, Université de Poitiers, Poitiers, France.; INSERM Clinical Investigation Center 1402, University Hospital Center of Poitiers, Poitiers, France.; Hematology Department, University Hospital Center of Poitiers, Poitiers, France.<br /><searchLink fieldCode="AU" term="%22Nsiala+L%22">Nsiala L</searchLink>; Poitou-Charentes General Cancer Registry, Université de Poitiers, Poitiers, France.; INSERM Clinical Investigation Center 1402, University Hospital Center of Poitiers, Poitiers, France.; Hematology Department, University Hospital Center of Poitiers, Poitiers, France.<br /><searchLink fieldCode="AU" term="%22Bobin+A%22">Bobin A</searchLink>; INSERM Clinical Investigation Center 1402, University Hospital Center of Poitiers, Poitiers, France.; Hematology Department, University Hospital Center of Poitiers, Poitiers, France.<br /><searchLink fieldCode="AU" term="%22Gardeney+H%22">Gardeney H</searchLink>; INSERM Clinical Investigation Center 1402, University Hospital Center of Poitiers, Poitiers, France.; Hematology Department, University Hospital Center of Poitiers, Poitiers, France.<br /><searchLink fieldCode="AU" term="%22Motard+C%22">Motard C</searchLink>; Hematology Department, Hospital Center of Niort, Niort, France.<br /><searchLink fieldCode="AU" term="%22Olivier+G%22">Olivier G</searchLink>; Hematology Department, Hospital Center of Niort, Niort, France.<br /><searchLink fieldCode="AU" term="%22Borde+F%22">Borde F</searchLink>; Oncology Department, Hospital Center of Saintes, Saintes, France.<br /><searchLink fieldCode="AU" term="%22Corby+A%22">Corby A</searchLink>; Hematology Department, Hospital Center of La Rochelle, La Rochelle, France.<br /><searchLink fieldCode="AU" term="%22Roul+C%22">Roul C</searchLink>; Hematology Department, Hospital Center of La Rochelle, La Rochelle, France.<br /><searchLink fieldCode="AU" term="%22Fleck+E%22">Fleck E</searchLink>; Hematology Department, Hospital Center of La Rochelle, La Rochelle, France.<br /><searchLink fieldCode="AU" term="%22Denis+G%22">Denis G</searchLink>; Internal Medicine Department, Hospital Center of Rochefort, Rochefort, France.<br /><searchLink fieldCode="AU" term="%22Dieval+C%22">Dieval C</searchLink>; Internal Medicine Department, Hospital Center of Rochefort, Rochefort, France.<br /><searchLink fieldCode="AU" term="%22Mottaz+P%22">Mottaz P</searchLink>; Internal Medicine Department, Hospital Center of Royan, Royan, France.<br /><searchLink fieldCode="AU" term="%22Boscagli+A%22">Boscagli A</searchLink>; Internal Medicine Department, Hospital Center of Royan, Royan, France.<br /><searchLink fieldCode="AU" term="%22Defossez+G%22">Defossez G</searchLink>; Poitou-Charentes General Cancer Registry, Université de Poitiers, Poitiers, France.; INSERM Clinical Investigation Center 1402, University Hospital Center of Poitiers, Poitiers, France.<br /><searchLink fieldCode="AU" term="%22Leleu+X%22">Leleu X</searchLink>; INSERM Clinical Investigation Center 1402, University Hospital Center of Poitiers, Poitiers, France.; Hematology Department, University Hospital Center of Poitiers, Poitiers, France.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101698425%22">Blood advances</searchLink> [Blood Adv] 2025 Dec 09; Vol. 9 (23), pp. 6001-6008.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+of+Hematology%22">American Society of Hematology </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101698425 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>2473-9537 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2224739529%22">24739529 </searchLink><i>NLM ISO Abbreviation: </i>Blood Adv <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40864187
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1182/bloodadvances.2025016625
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 6001
    Titles:
      – TitleFull: Risk of synchronous and second primary malignancies in transplant-ineligible patients with multiple myeloma treated with lenalidomide.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Systchenko T
      – PersonEntity:
          Name:
            NameFull: Nsiala L
      – PersonEntity:
          Name:
            NameFull: Bobin A
      – PersonEntity:
          Name:
            NameFull: Gardeney H
      – PersonEntity:
          Name:
            NameFull: Motard C
      – PersonEntity:
          Name:
            NameFull: Olivier G
      – PersonEntity:
          Name:
            NameFull: Borde F
      – PersonEntity:
          Name:
            NameFull: Corby A
      – PersonEntity:
          Name:
            NameFull: Roul C
      – PersonEntity:
          Name:
            NameFull: Fleck E
      – PersonEntity:
          Name:
            NameFull: Denis G
      – PersonEntity:
          Name:
            NameFull: Dieval C
      – PersonEntity:
          Name:
            NameFull: Mottaz P
      – PersonEntity:
          Name:
            NameFull: Boscagli A
      – PersonEntity:
          Name:
            NameFull: Defossez G
      – PersonEntity:
          Name:
            NameFull: Leleu X
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 09
              M: 12
              Text: 2025 Dec 09
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2473-9537
          Numbering:
            – Type: volume
              Value: 9
            – Type: issue
              Value: 23
          Titles:
            – TitleFull: Blood advances
              Type: main
ResultId 1